No Data
No Data
AIM ImmunoTech Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
Virtual Investor Releases Next Wave of "Top 5 for '25" On-Demand Videos
Express News | AIM ImmunoTech Form 4 Filing Shows CEO Thomas K Equels Bought 50,000 Shares At An Average Price Of $0.13/Share
CEO Makes Bold Move With Major AIM ImmunoTech Stock Purchase
Insider Purchase: CEO & President of $AIM Buys 83,334 Shares
AIM Announces Paul Goepfert, MD, as the Principal Investigator for the Planned Clinical Study of Ampligen and FluMist as a Vaccine for Avian Influenza